Overview

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatment for muscle wasting and weakness in myotonic dystrophy type 1.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Rochester

Collaborators:

Imsmed Incorporated
National Institute of Neurological Disorders and Stroke (NINDS)